Stockscreener 앱 받기
1.42
12.70%
0.16
시간 외 거래:
1.45
0.03
+2.11%
전일 마감가:
$1.26
열려 있는:
$1.29
하루 거래량:
2.33M
Relative Volume:
1.97
시가총액:
$127.09M
수익:
-
순이익/손실:
$-19.58M
주가수익비율:
-5.5103
EPS:
-0.2577
순현금흐름:
$-20.25M
1주 성능:
+24.56%
1개월 성능:
+24.56%
6개월 성능:
-2.74%
1년 성능:
+407.14%
1일 변동 폭
$1.25
$1.475
1주일 범위
$1.125
$1.475
52주 변동 폭
$0.25
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.42 | 108.29M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
CGTX Q1 2026 Earnings: EPS Beat Exceeds Estimates; Cash Runway Supports Alzheimer’s ProgramsShare Repurchase Impact - newsline.com
Cognition Therapeutics (CGTX) Rises 5.26% as Shares Approach Key ResistanceBullish Pattern Stocks - newsline.com
Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cognition Therapeutics (CGTX) Slips 5% as Biotech Momentum FadesIndex Put Call - newsline.com
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial - TipRanks
Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027 - TradingView
[8-K] COGNITION THERAPEUTICS INC Reports Material Event - Stock Titan
Cognition Therapeutics Reviews Phase 2 Results With FDA - asatunews.co.id
Cognition Therapeutics Meets FDA and Reduces First Quarter Net Loss - HarianBasis.co
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Insider Monkey
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at June Financial Conferences on DLB Psychosis Registration Program - Quiver Quantitative
Cognition Therapeutics Participating in Upcoming Investor Conferences - The Manila Times
CGTX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress for Alzheimer’s PipelineFull Year Guidance - newsline.com
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower‑than‑Expected Loss as Clinical Progress ContinuesPreliminary Results - newsline.com
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key SupportPrice Momentum Stocks - The Legal Advocate
CGTX Stock Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Holds Steady Near Key Support LevelRatio Spread Trade - newsline.com
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
CGTX Stock Price, Quote & Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Slides 1.59% as Biotech Sector Headwinds PersistSentiment Shift - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Slips Modestly as Stock Hovers Near Support ZoneBPI Bear Confirmed - The Legal Advocate
CGTX Q1 2026 Earnings: Narrower Loss Exceeds Estimates as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - Newser
CGTX Q1 2026 Earnings: Cognition Therapeutics Reports Narrower-Than-Expected Loss, No Revenue YetShort-Term Outlook - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower Loss on Lower Expenses, No Revenue ReportedGuidance Revision Trend - The Legal Advocate
Cognition Therapeutics Advances Zervimesine (CT1812) Toward Registrational Trial for Dementia with Lewy Bodies Psychosis After Positive FDA Meeting - Minichart
Cognition Therapeutics discusses FDA meeting on DLB drug trial By Investing.com - Investing.com South Africa
Cognition Therapeutics discusses FDA meeting on DLB drug trial - Investing.com
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial - TipRanks
Cognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies Psychosis - Quiver Quantitative
Cognition Therapeutics completes FDA meeting, sees path for registrational DLB psychosis program - TradingView
Cognition Therapeutics (CGTX) outlines FDA path for zervimesine DLB psychosis trial - Stock Titan
FDA, Cognition discuss next trial for Lewy body dementia psychosis drug - Stock Titan
Cognition Therapeutics Completes Meeting with FDA for - GlobeNewswire
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - The Chronicle-Journal
CGTX Should I Buy - Intellectia AI
TradingKey - TradingKey
Cognition Therapeutics receives donation to extend DLB program By Investing.com - Investing.com Australia
Cognition Therapeutics receives donation to extend DLB program - Investing.com
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - The Manila Times
Donor extends 2-year access to experimental DLB therapy for 32 people - Stock Titan
Press Release: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia With Lewy Bodies - Moomoo
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Chardan Capital Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
COGNITION THERAPEUTICS INC 1Q 2026: Net income $(4.57M), EPS $(0.05) — 10-Q Summary - TradingView
Cognition Therapeutics (NASDAQ: CGTX) Q1 2026 loss narrows on lower R&D - Stock Titan
The fundamentals driving Cognition (CGTX) everyone should understand (Smart Money Outflows) 2026-05-08Volume Dry Up - The Legal Advocate
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) cuts Q1 2026 loss and projects cash runway into Q2 2027 - Stock Titan
Dementia-drug developer gets May 20 FDA meeting as 2027 data loom - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cognition Therapeutics Inc 주식 (CGTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ricciardi Lisa | CEO & President |
Apr 16 '26 |
Buy |
1.10 |
9,175 |
10,092 |
1,715,851 |
| Caggiano Anthony | Chief Medical Officer |
Apr 16 '26 |
Buy |
1.11 |
10,000 |
11,100 |
874,906 |
| Fletcher Aaron G.L. | Director |
Sep 19 '25 |
Option Exercise |
0.84 |
7,729 |
6,492 |
56,229 |
2.60%
0.94%
자본화:
|
볼륨(24시간):